Bionano Genomics Acquires Purigen Biosystems

Artis BioSolutions To Acquire Syngoi Technologies

January 6, 2026

Biotechnology

Artis BioSolutions has signed a definitive agreement to acquire Syngoi Technologies, a Bilbao, Spain-based biotech developing enzymatic approaches for manufacturing synthetic DNA. The deal is intended to add fast, lower-cost synthetic DNA manufacturing to Artis’ gene-to-drug advanced-therapy platform, with Syngoi’s Bilbao GMP-ready facilities becoming part of Artis’ global footprint.

Standard BioTools Acquires Sengenics from Summa Equity

November 21, 2024

Biotechnology

Standard BioTools Inc. has acquired Sengenics Corporation Pte Ltd, a Summa Equity portfolio company, to broaden its proteomics and antibody‑profiling capabilities. The deal will integrate Sengenics' KREX™ immunoproteomics and i-OME™ Discovery platform with Standard BioTools' SomaScan/proteomics offerings to enhance biomarker discovery and accelerate drug development.

Biotage AB Acquires ATDBio

October 20, 2021

Biotechnology

Swedish life sciences company Biotage AB has acquired UK-based oligonucleotide specialist ATDBio for approximately £45 million in cash and shares. The deal brings ATDBio’s complex DNA/RNA synthesis capabilities and its founders into the Biotage Group to accelerate capability expansion and scale molecular diagnostics, therapeutics and sequencing support services.

Bionano Genomics Acquires BioDiscovery

October 12, 2021

Software

Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.

Pacific Biosciences Acquires Omniome

July 20, 2021

Biotechnology

Pacific Biosciences (PacBio) signed a definitive agreement to acquire San Diego-based Omniome for approximately $600 million in upfront consideration (9.4 million PacBio shares plus $300 million cash) plus up to $200 million in cash and stock tied to milestones, valuing the deal at about $800 million. The deal — supported by a concurrent $300 million PIPE financing — brings Omniome’s high-accuracy short-read Sequencing-by-Binding technology into PacBio’s portfolio of high-accuracy long-read SMRT sequencing systems to expand PacBio’s capabilities and address high-growth clinical markets such as oncology, transcriptomics and NIPT.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.